Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK3 | P52333 | 1/20 | 0.53 |
| ▸ | STK17B | O94768 | 7/20 | 0.51 |
| ▸ | STK17A | Q9UEE5 | 7/20 | 0.51 |
| ▸ | BRD4 | O60885 | 1/20 | 0.49 |
| ▸ | CCNK | O75909 | 2/20 | 0.49 |
| ▸ | CCND3 | P30281 | 2/20 | 0.49 |
| ▸ | CDK9 | P50750 | 2/20 | 0.49 |
| ▸ | CDK6 | Q00534 | 2/20 | 0.49 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.48 |
| ▸ | SYK | P43405 | 1/20 | 0.48 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.46 |
| ▸ | AURKA | O14965 | 1/20 | 0.46 |
| ▸ | EGFR | P00533 | 2/20 | 0.45 |
| ▸ | BTK | Q06187 | 2/20 | 0.45 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.45 |
| ▸ | CDK2 | P24941 | 1/20 | 0.45 |
| ▸ | CNR2 | P34972 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2519106 | 0.95 | STK17A (0.52) | JAK3STK17BSTK17ABRD4CCNK | |
| SCHEMBL2516086 | 0.94 | STK17A (0.52) | JAK3STK17BSTK17ABRD4CCNK | |
| SCHEMBL2514431 | 0.94 | JAK3 (0.53) | JAK3STK17BSTK17ABRD4CCNK | |
| SCHEMBL2521945 | 0.92 | CCNK (0.57) | JAK3BRD4CCNKCCND3CDK9 | |
| SCHEMBL2516090 | 0.90 | STK17A (0.52) | JAK3STK17BSTK17ABRD4CCNK | |
| SCHEMBL2519243 | 0.87 | CCNK (0.56) | JAK3BRD4CCNKCCND3CDK9 | |
| SCHEMBL3708248 | 0.85 | JAK3 (0.49) | JAK3STK17BSTK17ABRD4CCNK | |
| SCHEMBL2518058 | 0.84 | NTRK1 (0.63) | JAK3BRD4CCNKCCND3CDK9 | |
| SCHEMBL13283861 | 0.83 | CCNK (0.58) | JAK3BRD4CCNKCCND3CDK9 | |
| SCHEMBL2514435 | 0.83 | CCNK (0.64) | JAK3BRD4CCNKCCND3CDK9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8765727-B2 | Macrocyclic compounds and their use as kinase inhibitors | INCYTE CORPORATION (US) | 2014-07-01 | — | — | US | disclosed |
| US-8765727-B2 | Macrocyclic compounds and their use as kinase inhibitors | INCYTE CORPORATION (US) | 2014-07-01 | — | — | US | disclosed |
| US-8765727-B2 | Macrocyclic compounds and their use as kinase inhibitors | INCYTE CORPORATION (US) | 2014-07-01 | — | — | US | disclosed |
| US-20110251215-A9 | MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | INCYTE CORPORATION (US) | 2011-10-13 | — | — | US | disclosed |
| US-20110251215-A9 | MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | INCYTE CORPORATION (US) | 2011-10-13 | — | — | US | disclosed |
| US-20110251215-A9 | MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | INCYTE CORPORATION (US) | 2011-10-13 | — | — | US | disclosed |
| US-20100190804-A1 | MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | INCYTE CORPORATION (US) | 2010-07-29 | — | — | US | disclosed |
| US-20100190804-A1 | MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | INCYTE CORPORATION (US) | 2010-07-29 | — | — | US | disclosed |
| US-20100190804-A1 | MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | INCYTE CORPORATION (US) | 2010-07-29 | — | — | US | disclosed |
| WO-2010085597-A1 | MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | INCYTE CORPORATION (US) | 2010-07-29 | — | — | WO | disclosed |
| WO-2010085597-A1 | MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | INCYTE CORPORATION (US) | 2010-07-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110251215-A9 | MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | JAK2, JAK1, ALK | JAK3 4/4885STK17B 139/4885STK17A 74/4885 |
| US-20100190804-A1 | MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | JAK2, JAK1, ALK | JAK3 4/4885STK17B 139/4885STK17A 74/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.